These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28498301)

  • 21. Hepatitis A seroprevalence in public school children in Campos dos Goytacazes, Rio de Janeiro State, Brazil, prior to the introduction of the hepatitis A universal childhood vaccination.
    Kury CM; Pinto MA; Silva JP; Cruz OG; Vitral CL
    Cad Saude Publica; 2016 Nov; 32(11):e00175614. PubMed ID: 27982290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain.
    Domínguez A; Oviedo M; Carmona G; Jansá JM; Borrás E; Salleras L; Plasència A
    J Viral Hepat; 2008 Oct; 15 Suppl 2():51-6. PubMed ID: 18837835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence of hepatitis A in Iranian adolescents: is it time to introduce a vaccine?
    Hoseini SG; Kelishadi R; Ataei B; Yaran M; Motlagh ME; Ardalan G; Tajadini MH; Mostafavi SN
    Epidemiol Infect; 2016 Jan; 144(2):291-6. PubMed ID: 26083105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy.
    Ahmed M; Munshi SU; Nessa A; Ullah MS; Tabassum S; Islam MN
    Indian J Med Microbiol; 2009; 27(1):48-50. PubMed ID: 19172060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Introduction of routine hepatitis A immunization in Israel--the first in the world].
    Anis E; Leventhal A; Roitman M; Slater PE
    Harefuah; 2000 Feb; 138(3):177-80, 272. PubMed ID: 10883087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis a in Korea: epidemiological shift and call for vaccine strategy.
    Lee D; Cho YA; Park Y; Hwang JH; Kim JW; Kim NY; Lee DH; Lee W; Jeong SH
    Intervirology; 2008; 51(2):70-4. PubMed ID: 18434743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in the incidence of type 1 diabetes among Jews and Arabs in Israel.
    Blumenfeld O; Dichtiar R; Shohat T;
    Pediatr Diabetes; 2014 Sep; 15(6):422-7. PubMed ID: 24283719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis A virus infection in Taipei in 1999.
    Tseng HY; Lu CY; Lee CY; Yeh CC; Lin SC; Shih WY; Wu SY; Chang MH; Huang LM
    J Formos Med Assoc; 2001 Sep; 100(9):604-7. PubMed ID: 11695275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with childhood influenza vaccination in Israel: a cross-sectional evaluation.
    Glatman-Freedman A; Amir K; Dichtiar R; Zadka H; Vainer I; Karolinsky D; Enav T; Shohat T
    Isr J Health Policy Res; 2019 Nov; 8(1):82. PubMed ID: 31771629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adult infection with hepatitis A despite declining endemicity; in favor of adult vaccination.
    Gillis D; Grotto I; Mimouni D; Huerta M; Gdalevich M; Shpilberg O
    Vaccine; 2002 May; 20(17-18):2243-8. PubMed ID: 12009279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study.
    Xiaojin S; Rodewald LE; Guomin Z; Hui Z; Ning M; Fuzhen W; Zundong Y
    Vaccine; 2020 Dec; 38(52):8302-8309. PubMed ID: 33213930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study.
    Domínguez A; Bruguera M; Plans P; Espuñes J; Costa J; Plasencia A; Salleras L
    BMC Infect Dis; 2007 Jul; 7():73. PubMed ID: 17610736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.
    Mossong J; Putz L; Patiny S; Schneider F
    Epidemiol Infect; 2006 Aug; 134(4):808-13. PubMed ID: 16436219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis A immunity in Yozgat, Turkey.
    Kader Ç; Göçmen AY; Demir MI; Çolak NY; Gök SE; Arkan FI; Sara MY; Erbay A
    Ann Saudi Med; 2019; 39(1):37-41. PubMed ID: 30712049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis A disease following the implementation of universal vaccination: who is at risk?
    Mor Z; Srur S; Dagan R; Rishpon S
    J Viral Hepat; 2010 Apr; 17(4):293-7. PubMed ID: 19691457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Hepatitis A vaccination with a two-dose schedule in Panama: Results of epidemiological surveillance and time trend analysis.
    Estripeaut D; Contreras R; Tinajeros O; Castrejón MM; Shafi F; Ortega-Barria E; DeAntonio R
    Vaccine; 2015 Jun; 33(28):3200-7. PubMed ID: 25981490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine.
    Zamir C; Rishpon S; Zamir D; Leventhal A; Rimon N; Ben-Porath E
    Eur J Clin Microbiol Infect Dis; 2001 Mar; 20(3):185-7. PubMed ID: 11347668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The seroprevalence of West Nile Virus in Israel: A nationwide cross sectional study.
    Bassal R; Shohat T; Kaufman Z; Mannasse B; Shinar E; Amichay D; Barak M; Ben-Dor A; Bar Haim A; Cohen D; Mendelson E; Lustig Y
    PLoS One; 2017; 12(6):e0179774. PubMed ID: 28622360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling the decline and future of hepatitis A transmission in Australia.
    Jayasundara D; Hui BB; Regan DG; Heywood AE; MacIntyre CR; Wood JG
    J Viral Hepat; 2019 Jan; 26(1):199-207. PubMed ID: 30315680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.